Role of parenteral cephalosporins for outpatients treatment of infections;Criteri di scelta degli antibiotici nel trattamento domiciliare delle infezioni: Ruolo delle cefalosporine iniettabili

Infezioni in Medicina

Volumn 9, Issue 4, 2001, Pages 193-211

  Esposito, Silvano ^a   Mazzei, Teresita ^a   Novelli, Andrea ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cephalosporin; Outpatient antibiotic treatment

Indexed keywords

AMIKACIN; AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFODIZIME; CEFONICID; CEFOTAXIME; CEFOTETAN; CEFPODOXIME PROXETIL; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; NETILMICIN; PEFLOXACIN; PIPERACILLIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; DRUG HALF LIFE; FEMALE; HEALTH PROGRAM; HUMAN; MALE; OSTEOMYELITIS; OUTPATIENT CARE; RESPIRATORY TRACT INFECTION; REVIEW; SOFT TISSUE INFECTION;

AMBULATORY CARE; BACTERIAL INFECTIONS; CEPHALOSPORINS; HUMANS; ITALY;

EID: 0035696975     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Intravenous antibiotic treatment outside the hospital: Safety and healthy economic aspects
2. Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae
3. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
4. Pediatric consideration. Symposium on outpatient parenteral antibiotic therapy
5. Otolaryngology and infectious diseases team approach for outpatient management of serious pediatric infections requireing parenteral antibiotic therapy
6. Responses of children to hospitalization
7. Hospitalization decision in acquired pneumonia: A prospective cohort study
8. Parenteral antibiotic therapy in outpatients: Quality assurance and other issues in a protohospital
9. Amoxycillin/clavulanic acid: A review of its efficacy in over 38,500 patients from 1979 to 1992
10. Chronopharmacokinetics of sulphamethoxazole in human volunteers
11. Home intravenous antibiotic therapy (HIVAT): Indications, patients and antimicrobial agents
12. Outpatient parenteral antibiotic therapy: Selecting the patient
13. Pharmacokinetics: The dynamics of drug absorption, distribution and elimination
14. Antimicrobial resistance issues of the future
15. Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics
16. Pneumococcal resistance patterns in Europe
17. Evoluzione dell'antibiotico terapia: Una battaglia tra germi e farmaci
18. Sensitivity of Escherichia coli to various betalactams is determined by the interplay of outer membrane permeability and degradation by periplasmic β-lactamases: A quantitative predictive treatment
19. Molecular basis of bacterial outer membrane permeability
20. Role of permeability barriers in resistance to betalactam antibiotics
21. Outer membrane permeability of Gram-negative rods to cephalosporins
22. Ceftriaxone: Spectrum of activity, pharmacokinetics and pharmacodynamics
23. Polarità ionica delle betalattamine e prerogative antibiotiche: Razionale di una classificazione chimica
24. Classificazione delle betalattamine cefemiche: Le multipolari ioniche nello sviluppo generazionale
25. Attualità delle cefalosporine nella chemioterapia antimicrobica
26. In vitro evaluation of ceftriaxone activity against recent Gram-positive clinical isolates: Results from TSN database-USA, 1996-2000
27. In vitro evaluation of ceftriaxone activity against recent Gram-negative clinical isolates: Results from TSN database-USA, 1996-2000
28. Attuali orientamenti nella scelta e modalità di somministrazione degli agenti antimicrobici per una razionale chemioterapia delle sepsi grave
29. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: A review
30. Target for bacteriostatic and bactericidal activities of betalactam antibiotics against Escherichia coli resides in different penicillin-binding proteins
31. Betalattamine cefemiche parenterali ad azione prolungata
32. Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin
33. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
34. Postantibiotic effects in experimental infection models: Relationship to in vitro phenomena and to treatment of infections in man
35. Postantibiotic effect
36. Pharmacokinetic contributions to postantibiotic effects
37. Antimicrobial agents: Penicillins, cephalosporins and other beta-lactam antibiotics
38. Extravascular antimicrobial distribution and the respective blood concentrations in humans
39. Clinical pharmacokinetics of newer cephalosporins
40. Studio sul rapporto fra farmacocinetica e attività antibatterica: Confronto fra ceftriaxone e cefotaxime nell'apparato respiratori
41. Rassegna di dati di farmacocinetica del ceftriaxone: Conferme e novità relative a dieci anni di esperienza
42. Concentrations of cefodizime (HR-221] in pulmonary tissue after ripeated intravenous injections of lg of cefodizime
43. Distribuzione polmonare e tonsillare di ceftriaxone e cefonicid e risultante attività battericida d'organo
44. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
45. Pulmonary penetration of ceftazidime
46. The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances
47. Valutazione microbiologica e farmacinetica del cefonicid, una cefalosporina a lunga emivita
48. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function
49. Penetration of cefotetan into suction blister fluid and tissue homogenates in patients undergoing abdominal surgery. Cefotetan tissue penetration
50. Il cefonicid, cefalosporina parenterale ad azione prolungata
51. Cefodizime in skin suction blister fluid and serum following a single intravenous or intramuscular dose in adult patients
52. Antibiotic dosing-does one size fit all?
53. Kinetics of antibiotics in relation to effective and convenient outpatient parenteral therapy
54. Plasma protein binding and pharmacological response
55. Clinical pharmacokinetics of newer antibacterial agents in liver disease
56. A comparison of the pharmacokinetics and tissue penetration of ceftriaxone, moxalactam and cefotaxime
57. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use
58. Absolute bioavailability of ceftriaxone after intramuscular administration to healthy volunteers
59. Interaction of cephalosporins with human and canine serum proteins
60. Considerations in dosage selection for third generation cephalosporins
61. Rilevanza clinica del legame proteico degli antibiotici con particolare riferimento alle betalattamine cefemiche
62. Protein binding and the antimicrobial effects: Methods for the determination of protein binding
63. Penetration of cefotetan into suction blister fluid and tissue homogenates in patients undergoing abdominal surgery. Cefotetan tissue penetration
64. The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics
65. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: Clinically useful concepts
66. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers
67. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection
68. Pharmacokinetic profile. Ceftriaxone
69. Pharmacokinetics and safety of ceftriaxone in the neonate
70. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: A study of once daily administration by intramuscular and intravenous routes
71. Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile
72. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients
73. Treatment of streptococcal endocarditis with single daily dose of ceftriaxone sodium for four weeks. Efficacy and outpatient treatment feasibility
74. Antibiotic management of outpatients with endocarditis due to penicillin susceptible streptococci
75. Ceftriaxone sodium therapy of penicillin G-susceptible streptococcal endocarditis
76. Home intravenous antibiotic therapy for patients with infective endocarditis
77. Outpatient parenteral antibiotic therapy: Meningitis
78. Outpatient parenteral antibiotic therapy: Pelvic inflammatory disease
79. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient setting
80. Cefonicid in a once-daily regimen for treatment of osteomyleitis in an ambulatory setting
81. Experience with oupatient intravenous teicoplanin therapy for chronic osteomyelitis
82. Outpatient parenteral antimicrobial therapy for osteomyelitis
83. Outpatient parenteral antibiotic therapy: Pneumonia and chronic lung disease
84. Home treatment of pulmonary infections in cystic fibrosis
85. Home intravenous antibiotic treatment of patients with cystic fibrosis
86. Antibiotic-resistant pneumococci
87. Cellulitis
88. Outpatient parenteral anti-infective therapy for skin and soft tissue infections
89. Treatment of pyelonephritis in an observation unit
90. Treatment of acute pyelonephritis in women with intramuscular ceftriaxone: An outpatient study
91. Outpatient parenteral antibiotic therapy: Pyelonephritis
92. Risk assessment in cancer patients with fever and neuropenia: A prospective, two-center validation of a preiction rule
93. The outpatient management of febrile neutropenia in cancer patients
94. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day-hospital for hematologic malignancies
95. La neutropenia febbrile nel paziente onco-ematologico. Diagnosi e terapia
96. La terapia antimicrobica nel paziente granulocitopenico
97. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia
98. Outpatient management of acute myeloid leucemia after consolidation chemotherapy. Role of a hematologic emergency unit
99. Management of infective complications in patients with advanced hematologic malignancies in home care
100. A program of outpatient parenteral antibiotic therapy for serious pediatric bacterial infections
101. Once daily Ceftriaxone in the outpatient treatment of paediatric infections
102. Ruolo della terapia antibiotica iniettiva domiciliare